Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Morphochem provides novel lead compounds for further development from successful collaboration
Morphochem is a 2002 Tornado100 Winner


Munich, Germany, 20th May 2005...Morphochem AG, a leader in the evolutionary discovery of small molecule drugs today announced the successful completion of their first research agreement with Novartis, with the licensing of certain compounds discovered by Morphochem for further development at Novartis.
Under the terms of the agreement, Morphochem has applied the MOREsystem®, its proprietary design, synthesis and screening technology, to identify novel small molecules outside of existing Intellectual Property, against three non disclosed targets provided by Novartis.


For the duration of the agreement, Morphochem received research funding and is eligible for future milestone payments on the licensed compounds. 'We are very pleased that we could demonstrate the speed and efficiency of Morphochem's discovery engine to identify novel, 'drug-able' molecules outside existing intellectual property, so as to provide Novartis with alternative options for their development programs' Sijmen de Vries, MD, MBA, Chief Executive Officer of Morphochem, stated.


Notes
Morphochem AG (www.morphochem.com) a privately owned company based in Munich and Basel has developed a unique and highly integrated fast chemical genomics Drug Discovery Engine that it is applying in several 3th party research programs and for building its own fully owned pipeline. The current lead products in this pipeline; MCM 17 a novel oral anti-thrombotic (Factor Xa inhibitor) and MCB3837 a unique Oxaquin® Dual Action IV Hospital Antibiotic are planned to enter Clinical Trials towards the end of 2005. In addition, as the fast Discovery Engine enables 'Fast Follower' development projects on 'hot targets', in addition, the Morphochem pipeline also contains a number of original lead- stage projects against various proven targets.
xx


Publisher Contact Information:

Morphochem AG
+49 (0)89 78 00 50
sijmen.devries@morphochem.de

Company profile of Morphochem AG
Past press releases of Morphochem AG.

Data


25,485
Tech investments
From our Online Data Service
16,495
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Mar 24€1.8MInternet services
Mar 22€1.8MOther Biotechnology & Healthcare
Mar 22N/AMedical devices
Mar 22N/AConsumer applications
Mar 22N/ANetwork management
Mar 21€3.3MGames
Mar 21€16.0MInternet services

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round

Jul 10
Komed Health
komed health to be supported by nokia and deutsche telekom





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.